Outlook Therapeutics Announces $5M Registered Direct Deal With GMS Ventures At $0.5855/Share

Benzinga Newsdesk www.benzinga.com Neutral 67.4%

Neg 0% Neu 67.4% Pos 0%

Comments

No comments yet. Be the first!